Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Company Overview

Akebia Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach. The company has partnered with Otsuka Pharmaceutical for filing and commercialization of vadadustat in the United States, while Mitsubishi Tanabe Pharma holds rights to develop and commercialize the compound in ex-Japan territories. These alliances leverage Akebia’s scientific expertise alongside the global commercialization networks of its partners.

In addition to its focus on anemia in kidney disease, Akebia evaluates novel mechanisms of action aimed at improving kidney health and patient outcomes. The company maintains clinical trial sites across North America and engages with healthcare providers, academic institutions and patient advocacy groups to support the design and execution of its studies. Under the leadership of President and Chief Executive Officer John P. Butler, Akebia continues to build its development infrastructure and prepare for potential regulatory milestones.

Key Stats

• Today's Range: $0.85 to $1.01
• 50-Day Range: $0.87 to $1.43
• 52-Week Range: $0.82 to $3.44
• Volume: 7.84 million shs
• Average Volume: 3.86 million shs
• Market Capitalization: $249.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.67
• Consensus Rating: Hold

Akebia Therapeutics Stock Analysis - MarketRank™

Akebia Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 501st out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Akebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Akebia Therapeutics has a consensus price target of $4.67, representing about 261.8% upside from its current price of $1.29.

Amount of Analyst Coverage

Akebia Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.10) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akebia Therapeutics is -16.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akebia Therapeutics is -16.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Akebia Therapeutics has a P/B Ratio of 10.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.43% of the float of Akebia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Akebia Therapeutics has recently decreased by 0.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akebia Therapeutics does not currently pay a dividend.

Dividend Growth

Akebia Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.20

News Sentiment

Akebia Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,181.00 in company stock.

Percentage Held by Insiders

4.30% of the stock of Akebia Therapeutics is held by insiders.

Percentage Held by Institutions

33.92% of the stock of Akebia Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AKBA
• CIK: 1517022
• Web: www.akebia.com
• Phone: (617) 871-2098
• Fax: 617-871-2099
• Employees: 430
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Akebia Therapeutics: $4.67
• High Price Target: $6.00
• Low Price Target: $4.00
• Potential Upside/Downside: +401.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.34 million
• Net Margins: -8.83%
• Pretax Margin: -8.07%
• Return on Equity: -62.72%
• Return on Assets: -5.66%

Debt

• Debt-to-Equity Ratio: 1.33
• Current Ratio: 1.40
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $236.20 million
• Price / Sales: 1.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 7.75

Miscellaneous

• Outstanding Shares: 268,260,000
• Free Float: 256,723,000
• Market Cap: $249.48 million
• Optionable: Optionable
• Beta: 0.26